Topic starter
18/08/2026 3:00 pm
TL;DR: SBOM accuracy is one of the controls that determines whether medical device teams can prove and maintain safety over time, according to Kusari's blog post. Evidence-ready traceability and lifecycle monitoring have to hold after release, or vulnerability response turns into guesswork.
Editorial analysis by NHI Mgmt Group, based on content published by Kusari: “Medical Device Cybersecurity & FDA 524B Compliance”.
Key questions
Q: When should device teams prioritise postmarket monitoring over premarket documentation?
A: They should prioritise postmarket monitoring as soon as the device ships, because vulnerability exposure continues after approval.
Q: What do teams get wrong about open source in medical devices?
A: They often treat open source as a procurement issue instead of an ongoing governance obligation.
Q: What breaks when a medical device SBOM is incomplete?
A: An incomplete SBOM breaks vulnerability triage, release tracing, and regulator-facing evidence.
Practitioner guidance
- Build release-linked SBOM governance Tie every device release to a versioned SBOM that maps components, hashes, and ownership to the shipped artifact.
- Operationalise postmarket vulnerability intake Create a workflow that matches disclosed vulnerabilities to affected device models, firmware versions, and customer deployments, then routes remediation decisions through a named owner.
- Assign dependency accountability Name owners for open source intake, patch validation, and license review so each dependency has a clear control path from adoption to retirement.
Bottom line: Medical device cybersecurity now depends on governance over embedded software, not just device hardening at deployment.
Glossary terms: Software Supply Chain Governance, Software Bill of Materials, Postmarket Cybersecurity Surveillance, Evidence-Ready Traceability
Explore further
View Full Forum → | NHI Foundation Course → | Our Services → | Read the full analysis →
This topic was modified 1 day ago by NHI Mgmt Group
18/08/2026 3:40 pm
Software supply chain governance has become part of medical device security, not a side control. The article reflects a broader shift in regulated technology: once third-party code ships inside the device, the burden is no longer limited to vendor assurances or point-in-time testing. Teams need traceability from component inventory to deployed build, otherwise cybersecurity evidence collapses into guesswork. For device programmes, this means governance must reach into the software bill of materials, release process, and ongoing vulnerability handling.
A few things that frame the scale:
- Software supply chain attacks were projected to cost organisations $60 billion in 2025.
A question worth separating out:
Q: How should regulated product teams manage software supply chain risk in connected devices?
A: They should manage it as a lifecycle control, not a one-time assessment. That means authoritative SBOMs, vulnerability intake, named ownership for dependencies, and evidence that updates can be traced from code change to shipped artifact. The goal is to make every device supportable after release.
👉 Read our full editorial: Medical device cybersecurity hinges on software supply chain governance